The addition of docetaxel to first-line long-term hormone therapy in patients with prostate cancer is associated with improved quality of life (QoL) benefits and cost effectiveness, according to study results presented at the 2018 Genitourinary Cancers Symposium.
The addition of docetaxel to first-line long-term hormone therapy in patients with prostate cancer is associated with improved quality of life (QoL) benefits and cost effectiveness, according to study results.
During a session at the 2018 Genitourinary Cancers Symposium, Nicholas James, MBBS, PhD, Queen Elizabeth Hospital, presented results from the STAMPEDE trial, which looked at patients with M0 and M1 disease. The primary outcome of the trial was overall survival, and secondary endpoints included failure-free survival (FFS), progression-free survival, metastatic progression-free survival, skeletal-related events (SRE), toxicity, cost effectiveness, and QoL.
“Docetaxel produced a very consistent improvement in FFS across the whole trial,” said James. “The other thing that was very consistent across the whole trial was a 40% reduction in symptomatic skeletal events.”
The researchers used a standard model-based approach, explained James. All patients start hormone sensitive and they can progress to M0 castrate-resistant prostate cancer (CRPC) or M1 lymph node disease, CRPC bone, CRPC bone with a SRE, or CRPC visceral. The STAMPEDE trial data were used to determine how much each patient spent time in each category and what the QoL implications were. Additionally, the researchers also assessed cost effectiveness.
Because M0 patients have a 40% delay in the time to relapse, the patients getting docetaxel upfront spend more time hormone sensitive than patients in the control arm, said James. They subsequently spend less time with CRPC M0 or M1 lymph node only, and also less time with bone metastases, with or without an SRE. This correlates to more time with relatively good QoL, and less time with relatively poor QoL. For the metastatic setting, the same effects were observed. Patients spend more time in the hormone-sensitive state. This means less time with the factors that harm your QoL and increase your costs, said James.
“For metastatic patients where there’s a survival advantage, not surprisingly, you see a quality-adjusted life years (QALY) gain as well,” said James. “In other words, the benefits of not relapsing, not having SREs, wipes out the quality of life penalty that you incur from your upfront chemotherapy.”
The same effect was seen in M0 patients. Although there wasn’t a robust survival advantage in this setting, there is still a QALY gain.
For treatment with docetaxel, end-of-life costs didn’t change substantially, docetaxel costs increased, management costs in general went up, and over the course of the trial, the costs of other life prolonging therapies went up. However, there’s been big changes over the duration of the trial with the emergence of androgen receptor targeted therapies, said James.
The researchers remodeled the data using patients who had enrolled later in the trial and who were getting abiraterone/enzalutamide for M1 CRPC. When they did that, there were still increases in docetaxel costs, management costs, and there was little effect on end-of-life care. However, there was a significant reduction in the use of other life prolonging therapies compared to the control arm. When looking at net total cost, there was a reduction in overall lifetime care costs in M0 disease from the upfront addition of docetaxel. While there was a net increase for the metastatic setting, the total cost was approximately £3000 over the lifetime of the patient.
“Upfront docetaxel results in robust gain in quality adjusted life years in all subgroups,” concluded James. “It supports existing healthcare policy in metastatic patients, but it also supports the use of docetaxel in high-risk non-metastatic patients.”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More